HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, No. 9, September 2016 – Infectious Diseases       » Curcumin Derivatives May Prevent Alzheimer's Disease by Promoting Amyloid- Clearance       » Varian Chosen to Equip First Government Owned Proton Centre in China       » Medtronic and SingHealth Collaborate on a Centre of Excellence to Fight Diabetes       » NCCS Awards Contract for Proton Beam Therapy System to Hitachi Asia      
BIOBOARD - AFRICA
RegeneCure's membrane implant shows 40% accelerated healing time of severe bone fractures
RegeneCure announced the successful results of a clinical study in pets using the company's regenerative membrane implant technology for the treatment of bone fractures. The study showed that the healing time was about 40 % quicker than normally observed using current Standard of Care therapies. The product was also demonstrated to be safe in all of the study participants.

"The healing time for animals treated in the participating clinical study sites with injuries that normally take from five to twelve months was in many cases reduced to just eight weeks," said Dr. Michal Limor, VP Medical Affairs of RegeneCure.

The multi-center trial was conducted at leading veterinary clinics in England, Germany and Israel. The study included 35 mature dogs and cats with different bone fractures including delayed healing and non-union conditions.

"The outstanding safety and efficacy results and additional data collected from pre-clinical studies, will enable us to proceed with a human clinical study in the near future," said Moshe Tzabari, CEO of RegeneCure.

When applied to humans, RegeneCure's membrane is expected to reduce healing time in current treatment and eliminate the need of secondary surgical intervention due to failure.

Due to the membrane capabilities, it can reduce the use of bone grafting and bone graft substitutes currently used in standard procedures. RegeneCure's membrane implant is suited for a large range of fresh or delayed long bone fractures, large bone defects and craniofacial conditions that are characterized by delayed or lack of bone healing due to bone deficit. The existing US orthopedic biomaterial market used in these human conditions is over $500 million.

Click here for the complete issue.

NEWS CRUNCH  
news Enterprise meets technology: More than 300 enabling innovations showcased at TechInnovation
news CPhI's Pre-Connect Congress outlines current trends in pharma
news World Population Day 2016
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Leading-Edge ONCOLOGY
May:
Healthcare Systems & Policies in Asia
June:
Medical Devices & Healthcare Technology
July:
Water Technology and Management
August:
Novel Technologies for Antibody Drug Discovery in Japan
September:
Infectious Diseases
October:
Medical Tourism
November:
Big Data in Healthcare
December:
Orthopaedics
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2016 World Scientific Publishing Co Pte Ltd  •  Privacy Policy